Results 351 to 360 of about 22,658,854 (391)
Some of the next articles are maybe not open access.

The Biology of Interleukin-2

Annual Review of Immunology, 2008
Much data support an essential role for interleukin (IL)-2 in immune tolerance. This idea is much different from the early paradigm in which IL-2 is central for protective immune responses. This change in thinking occurred when a T regulatory cell defect was shown to be responsible for the lethal autoimmunity associated with IL-2/IL-2R deficiency. This
openaire   +2 more sources

Soluble interleukin 2 receptor release, interleukin 2 production, and interleukin 2 receptor expression in activated T-lymphocytes in vitro

Pathology, 1991
Following activation in vitro, peripheral blood mononuclear cells (PBMC) express cell-associated interleukin-2 receptors (IL2R). The present study was undertaken to define the proportion of T lymphocyte subsets that express the IL2R (CD25 antigen) upon different mitogenic stimulation.
Lai, FM, Leung, JCK, Lai, KN
openaire   +5 more sources

The interleukin-2/interleukin-2 receptor system: structural, immunological, and clinical features

International Journal of Clinical & Laboratory Research, 1992
Interleukin-2 (IL-2) has been the first and more extensively studied cytokine, in particular for its central role in the mechanisms of cell growth and differentiation. The function of IL-2 is mediated through specific receptors (IL-2R) present on the membrane of reacting cells.
SEMENZATO, GIANPIETRO CARLO   +2 more
openaire   +5 more sources

Interleukin-2

Reactions weekly, 2021

semanticscholar   +1 more source

Interleukin-2 in cancer

Emerging Drugs, 2000
The development of recombinant interleukin-2 (rIL-2) as a treatment for cancer represented an important milestone in the development of biologic therapies. IL-2 is a natural modulator of the immune system that stimulates specialised immune system cells, namely cytotoxic T-lymphocytes (CTLs) and natural killer cells (NKCs). These cells could potentially
Anagha Gurjal, Philip Agop Philip
openaire   +2 more sources

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

New England Journal of Medicine, 1987
Adoptive immunotherapy involving bolus-dose recombinant interleukin-2 (rIL-2) has been reported to induce tumor regression in some patients with cancer, but has been associated with severe fluid retention and cardiopulmonary stress.
W. West   +6 more
semanticscholar   +1 more source

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

Journal of the American Medical Association (JAMA), 1994
OBJECTIVE To determine the efficacy of treatment using high-dose bolus interleukin 2 (IL-2) in patients with metastatic melanoma or renal cell cancer.
S. Rosenberg   +8 more
semanticscholar   +1 more source

Interleukin-2, Autotolerance, and Autoimmunity

1991
Insomma se il modello non riesce a trasformare la realta, la realta dovrebbe riuscire a trasformare il modello…. Se le cose stanno cosi, il modello dei modelli dovra servire a ottenere dei modelli trasparenti, diafani, sottili como ragnatele; magari addiritura a dissolvere i modelli, anzi a dissolversi.
José Luis Andreu   +4 more
openaire   +3 more sources

Clinical applications of interleukin-2

Progress in Growth Factor Research, 1992
Interleukin-2 (IL-2) is a cytokine with potent immunomodulating properties which has shown considerable antitumour activity in preclinical models. In clinical trials, the effects of IL-2 given by various routes and schedules have been investigated.
A. von Rohr, Nick Thatcher
openaire   +3 more sources

The human interleukin-2 receptor

Journal of Cell Science, 1985
ABSTRACT Complementary DNAs corresponding to the human receptor for interleukin-2 (IL-2) have been molecularly cloned, sequenced, and expressed in both COS-1 and L cells. The human genome appears to contain a single structural gene for this receptor located on the short arm of chromosome 10 (band 14-15).
Joel M. Depper   +3 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy